Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
WhiteSwell logo — A fundamental shift in the treatment of acute decompensated...

WhiteSwell

A fundamental shift in the treatment of acute decompensated heart failure

Founded 2014 Ireland Ireland 35 employees Series B Total: $30.00M Biotechnology, Health Care

General Information

Company Name WhiteSwell
Founded Year 2014
Location Ireland Ireland
Employees 35
Industries Biotechnology, Health Care
Funding Stage Series B
Social

BounceWatch is an independent company data service, not affiliated with WhiteSwell. To contact WhiteSwell, visit whiteswell.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does WhiteSwell compare?

A PDF of WhiteSwell and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting WhiteSwell soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About WhiteSwell

WhiteSwell is a science-driven startup with a slogan of "A fundamental shift in the treatment of acute decompensated heart failure." Founded in 2014 and based in Ireland, the company is dedicated to improving the treatment of acute decompensated heart failure (ADHF), a leading cause of repeated hospitalizations and emergency room visits. WhiteSwell is focused on pioneering a minimally invasive catheter-based approach aimed at more efficiently removing excess interstitial fluid in ADHF patients by enhancing the natural fluid removal process of the lymphatic system. The latest significant milestone for WhiteSwell was a $30.00M Series B investment on 11 December 2018. The investors involved in this round were RA Capital Management and InCube Ventures. For more information about WhiteSwell, interested parties can visit the company's website at www.whiteswell.com.

Business keywords: cardiology, innovation, lymphatic system, minimally invasive procedures, acute decompensated heart failure, catheter-based approach, fluid removal technology, clinical research, interstitial fluid management, therapeutic solutions, science-driven, hospital readmission reduction

Services & Products

Development of eLym™ System for the treatment of acute decompensated heart failure

Target Customers

Patients suffering from acute decompensated heart failure healthcare providers medical facilities

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Series B $30.00M 2
RA Capital Management InCube Ventures
RA Capital Management, InCube Ventures
11 Dec 2018

WhiteSwell Alternatives & Competitors

View All Alternatives
WhiteSwell vs
InterShunt Technologies, Inc.
InterShunt Technologies, Inc. United States

Heart Failure is one of the most debilitating medical issues we face. It is the leading cause of hos...

Non Equity Assistance
7 employees
Biotechnology, Health Care
Compare WhiteSwell vs InterShunt Technologies, Inc.
WhiteSwell vs
Second Heart Assist Inc.
Second Heart Assist Inc. United States

The world's most novel heart pump - revolutionizing the field of cardiology to better combat heart f...

Venture round
7 employees
Biotechnology, Health Care
Compare WhiteSwell vs Second Heart Assist Inc.
WhiteSwell vs
BioVentrix
BioVentrix United States

BioVentrix is a privately held medical device company headquartered in San Ramon, CA, USA. Our missi...

Series A
17 employees
Biotechnology, Health Care
View all alternatives

FAQ About WhiteSwell

A fundamental shift in the treatment of acute decompensated heart failure
WhiteSwell was founded in 2014.
WhiteSwell is headquartered in Ireland.
WhiteSwell operates in Biotechnology and Health Care. Its work centres on cardiology, innovation, lymphatic system and minimally invasive procedures. Its customers include Patients suffering from acute decompensated heart failure, healthcare providers and medical facilities.
WhiteSwell has approximately 35 employees.
WhiteSwell has completed 1 funding round, raising a total of $30.00M. The latest funding stage is Series B.
WhiteSwell offers: Development of eLym™ System for the treatment of acute decompensated heart failure.
Top alternatives and competitors to WhiteSwell include InterShunt Technologies, Inc., Second Heart Assist Inc., BioVentrix, Vixiar Medical, CryoTherapeutics SA. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
WhiteSwell and InterShunt Technologies, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for WhiteSwell, https://bouncewatch.com/company/whiteswell, updated 24 February 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes